Cardiothoracic Surgery Articles & Analysis
26 news found
Summary The SurgiCam® HD, a specialized point-of-view camera designed for clinicians, plays a pivotal role in the documentation, education, and analysis of surgical, dental, and veterinary procedures. Its high-quality image and video capturing capabilities make it an indispensable tool in these fields. This innovative camera significantly enhances surgical practices, education, and research ...
Joseph Coselli, MD (Professor, Executive Vice Chair, Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas, US) the Principal Investigator commented: “This approval represents a significant milestone in the treatment of patients who need total aortic arch replacement and have significant disease of the descending thoracic aorta. ...
CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. ...
To begin with, we plan to highlight last year’s NICE Medtech innovation briefing on the use of CytoSorb to reduce the risk of bleeding during cardiothoracic surgery in patients on blood thinning medications in the UK health system. ...
EchoPixel has had a long-standing relationship with Stanford physicians, who were early adopters of its technology, beginning with the successful surgery of the conjoined Sandoval twins in 2017. The affiliation has continued in partnership with Michael Ma, MD, Assistant Professor of Cardiothoracic Surgery in the Division of Pediatric ...
CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. ...
Small lesions in the lung are notoriously hard to locate during surgery. With broad application in radio-guided surgery across multiple procedures and major cancer types, SENSEI is currently in use worldwide in prostate, cervical, and colorectal cancer surgery. Dr. Doug Adams, Cardiothoracic Surgeon, Bethesda North Hospital ...
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
Wendt is Board-certified by the European Board of Cardiothoracic Surgery (FETCS) and also obtained his Master of Health Business Administration (MHBA) from the Friedrich-Alexander-University School of Business in Erlangen-Nuremberg, Germany. ...
CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. ...
The full Study enrollment will include plastic surgery, spinal surgery and cardiothoracic surgery closed incisions. ...
If FDA marketing approval is obtained by the FDA, DrugSorb-ATR™ would be marketed in the United States for ticagrelor removal during urgent cardiothoracic surgery, with the intention of reducing the risk of bleeding. ...
When patients on various “blood thinners”, like apixaban or rivaroxaban, require urgent cardiothoracic surgery, the risk of serious or life-threatening bleeding and complications is very high. Based on our estimates, at least 1% of patients in the U.S. on apixaban or rivaroxaban may require urgent cardiothoracic ...
Overall, infective endocarditis is just one of many applications of our technology in cardiac surgery and is a much smaller opportunity than the removal of antithrombotic drugs during cardiothoracic surgery, for which we have specific approvals in the E.U., two U.S. ...
Schmitto and his interdisciplinary Heart Team of the Department of Cardiothoracic and Transplant Surgery (Director: Prof. Axel Haverich) at Hannover Medical School (Medizinische Hochschule Hannover – MHH), in Germany. ...
ByCarmat
AdjuCor raises € 29 million to enable its next phase of bringing its revolutionary heart assist technology to the severely underserved end-stage heart failure patients. This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor ...
Approximately 53% of BAV patients require aortic valve surgery within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of reoperation or complications associated with valve replacement technologies. [2] Valve repair is an attractive alternative to valve replacement for bicuspid ...
In another great achievement for AdjuCor’s ground-breaking new technology within a short period of time, its submitted abstract has been accepted for presentation at the prestigious 101st American Association for Thoracic Surgery (#AATS2021). Prof. Stephan Schueler will be presenting specifics relating to the augmentation technology. ...
Panneton, M.D., FACS, FRCSC, Vascular Surgery Chief and Program Director, EVMS, Norfolk, VA “Some of these patients currently don’t have many options that don’t come with a high degree of risk” confirmed Christopher J. Barreiro, M.D., Cardiothoracic Surgeon, Sentara Mid-Atlantic Cardiothoracic Surgeons, Norfolk, VA ...
For the very first time, AdjuCor GmbH's revolutionary new heart-assist technology – BEAT – will take the stage at the prestigious 41st International Society for Heart and Lung Transplantation (#ISHLT2021). Prof. Ulrich Stock will be presenting BEAT’s acute and chronic preclinical results, proudly showcasing this first-in-class technology and how it can assist the failing heart. ...